Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

June 5-7, 2017
Paradise Point San Diego,
San Diego, CA

DRIVING CREATIVE PROTEIN ENGINEERING & DESIGN TO SUCCESSFULLY TRANSFORM PROMISING NEW MOLECULES INTO DIFFERENTIATED PRODUCTS

Get unparalleled coverage of the discovery, engineering, and development of novel protein therapeutics and bioconjugates.

Time is Running Out!

Online registration closes next Thursday, June 1st! Don't miss out!

Accelerate promising new molecules into differentiated products

Deep dive into new case studies and unpublished data to achieve greater clinical success with your own candidates.
  • Increase efficacy, potency, selectivity, and payload capacity
  • Design bi- and multi-specifics with novel modes of action
  • Discover new pathways for immunotherapies
  • Improve developability and drug-like properties
  • Engineer breakthroughs across diverse disease indications
  • Achieve delivery into cells and across the blood-brain barrier
Meet luminaries advancing molecular discovery, design, and development.
  • Learn from the many successes, obstacles, failures, and successes in the latest clinical results.
  • Help shape and expand the frontier for novel biologics at the 9 moderated roundtable discussions.
Increase your molecule's viability by collaborating across departments and stages of development.
  • Breakdown barriers between stages of development to improve manufacturability and clinical success rates.
  • Leverage 10+ networking opportunities and a shared exhibit hall to make new connections & advance your career.
  • Work collaboratively to overcome your greatest challenges from reducing risk to expediting timelines.

DIVE INTO BIOCONJUGATES! PERFECT THE BIOCHEMISTRY BEHIND ADC SYNTHESIS, VACCINE, AND NANOPARTICLE CONJUGATION

Develop Platforms to Support Novel Linkers and Payloads
  • Explore how the new class of DNA-alkylating agents are designed and synthesized
  • Mitigate toxicity risks and ensure proper potency with the latest data from Genentech and Immunogen
Take Your Products from Discovery to Commercialization
  • Combat analytical and characterization challenges with new data and case studies
  • Learn best practices for evaluating molecular complexity and critical quality attributes
  • Assess late-stage commercial readiness with experts from top pharmaceutical companies
Share Breakthroughs and Advances in Bioconjugation
  • Hear the latest data on bispecific, nano-particle, and vaccine conjugation
  • Eliminate heterogeneity and increase the therapeutic window with the newest and most relevant data

The Leading Meeting for Bioconjugates and Next Generation Protein Therapeutics

2 Tracks
Dedicated to Bioconjugates and Next Generation Protein Therapeutics
45+
Case Studies and New Data Presentations
250+
Attendees from Pharmaceutical, Biotech, and Solution Providers
10+
Years of growing into the favorite gathering place for world-renowned academic and industry visionaries.
60+
Experts and Scientists presenting new data and case studies
3 Days
For maximum network and knowledge share with your peers

Exclusive Whitepaper Downloads

Innovative Development Strategies and Applications for Bispecific Antibodies

The phenomenal growth of the bispecific antibody arena has culminated in 60 unique constructs, more than 30 in clinical development, and two on the market as therapeutics for a wide variety of cancer types and numerous diseases/disorders. Bispecific antibodies are specially engineered antibodies which simultaneously bind to two different epitopes on the same antigen or different antigens, increasing selectivity and effectiveness.

Creating New Pathways for the Development, Translation, and Delivery of Immunotherapies

The last decade has seen substantial growth of immunotherapy treatments for cancer. The new immunotherapies have produced exciting results in terms of response rates to treatment for certain cancers, such as melanoma, which have been refractory to treatment, once substantial metastasis has occurred. The US Food and Drug Administration (FDA) has approved several antibodies against immune checkpoint inhibitors based on the encouraging results in clinical trials. Other types of immune therapies are also being developed which may also be useful in the treatment of cancer.

Sponsorship & Exhibition Opportunities


Showcase the adaptability of your products to leading scientists representing the upstream development and bioprocessing chain, spanning early stage discovery to early stage development.

For more information or to begin building your custom sponsorship package today, contact Patty Rose at (857) 504-6689 or patricia.rose@knect365.com.